Byong Cho is a pioneer in the exosome industry and has served as founder, CEO, and CTO of ExoCoBio Inc. since 2017. With a background in molecular biology (BS, MSc) and a Techno-MBA from KAIST, he has over two decades of success in biotech management and venture capital, including the IPOs of Medytox and Viromed, now valued at a combined $5 billion.
Leveraging his expertise, he founded ExoCoBio to develop exosome-based regenerative therapeutics and aesthetics. He is the first author of a groundbreaking 2018 study demonstrating stem cell-derived exosomes as viable treatments for skin diseases like atopic dermatitis. He holds 70+ patents of a variety of exosome-based scientific discoveries and has authored or sponsored 33 scientific publications on exosomes for the last 7 years.
As a global thought leader, he has delivered 100+ lectures at prestigious events like IMCAS, AMWC, Dubai Derma, and WCD, advancing the field of exosome-based therapies worldwide since 2018.